Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891052 | 0.86 | S1PR1 (0.42) | TAAR1ACACBKDM4EKMT2ANPC1 | |
| SCHEMBL17427772 | 0.86 | PLK1 (0.44) | POLBCTDSP1ACACBKDM4ES1PR1 | |
| SCHEMBL24430171 | 0.86 | NPC1 (0.45) | KDM4ENPC1HPGDSMN1; SMN2S1PR1 | |
| SCHEMBL8496037 | 0.84 | S1PR1 (0.52) | POLBTAAR1LMNACYP1A2KDM4E | |
| SCHEMBL15958710 | 0.84 | ALDH1A1 (0.46) | POLBTAAR1LMNAKDM4EMAPT | |
| SCHEMBL589863 | 0.82 | KDM4E (0.39) | POLBCTDSP1TAAR1LMNAACACB | |
| SCHEMBL16202271 | 0.82 | LMNA (0.46) | POLBTAAR1LMNAACACBCYP1A2 | |
| SCHEMBL12064836 | 0.82 | TNNC1 (0.43) | LMNACYP1A2NPC1HPGDSMN1; SMN2 | |
| SCHEMBL5991714 | 0.82 | EPHX2 (0.39) | KDM4EKMT2AS1PR1 | |
| SCHEMBL8496762 | 0.81 | S1PR1 (0.60) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111087357-B | Preparation method of Prisamod | 中国医学科学院药物研究所 | 2022-07-19 | — | — | CN | disclosed |
| CN-111087356-B | Preparation method of Iguratimod | 中国医学科学院药物研究所 | 2022-06-21 | — | — | CN | disclosed |
| CN-111087357-A | Preparation method of Prisamod | 中国医学科学院药物研究所 | 2020-05-01 | — | — | CN | disclosed |
| CN-111087356-A | Preparation method of Iguratimod | 中国医学科学院药物研究所 | 2020-05-01 | — | — | CN | disclosed |
| EP-2017257-B1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-08-06 | — | — | EP | disclosed |
| EP-2017257-B1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8114902-B2 | 2-aminobutanol compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8114902-B2 | 2-aminobutanol compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8114902-B2 | 2-aminobutanol compound and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-2017257-A1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017257-A1 | 2-AMINOBUTANOL COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082311-A1 | 2-Aminobutanol Compound and Use Thereof for Medical Purposes | ADRB2, ADRB1, ADRB3 | POLB 2121/4885CTDSP1 3725/4885TAAR1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.